Exhibit 5.4
![LOGO](https://capedge.com/proxy/8-K/0001193125-20-257811/g19681snap7.jpg)
Medtronic, Inc.
710 Medtronic Parkway
Minneapolis MN 55432
www.medtronic.com
September 29, 2020
Medtronic, Inc.
710 Medtronic Parkway
Minneapolis, MN 55432
Re: Medtronic Global Holdings S.C.A. Senior Notes
Ladies and Gentlemen:
This opinion is furnished to you in connection with the offer and sale by Medtronic Global Holdings S.C.A, an entity organized under the laws of Luxembourg (“Medtronic Luxco”) of €1,250,000,000 aggregate principal amount of its 0.000% Senior Notes due 2023 (the “2023 Notes”), €1,000,000,000 aggregate principal amount of its 0.000% Senior Notes due 2025 (the “2025 Notes”), €1,000,000,000 aggregate principal amount of its 0.375% Senior Notes due 2028 (the “2028 Notes”), €1,000,000,000 aggregate principal amount of its 0.750% Senior Notes due 2032 (the “2032 Notes”), €1,000,000,000 aggregate principal amount of its 1.375% Senior Notes due 2040 (the “2040 Notes”), and €1,000,000,000 aggregate principal amount of its 1.625% Senior Notes due 2050 (the “2050 Notes”, and together with the 2023 Notes, the 2025 Notes, the 2028 Notes, the 2032 Notes and the 2040 Notes, the “Notes”), pursuant to the Underwriting Agreement dated September 24, 2020 (the “Underwriting Agreement”), among Medtronic Luxco, the Guarantors (as defined below), Barclays Bank PLC, BofA Securities Europe SA, Mizuho Securities Europe GmbH and Deutsche Bank Aktiengesellschaft, as representatives of the Underwriters party to the Underwriting Agreement. The Notes will be fully and unconditionally guaranteed on an unsecured unsubordinated basis by Medtronic, Inc., a Minnesota corporation (the “Company,” and such guarantee, the “Company Guarantee”) and Medtronic Public Limited Company, an entity incorporated under the laws of Ireland (“Medtronic plc,” and together with the Company, the “Guarantors”).
The Notes will be issued pursuant to the Indenture dated as of March 28, 2017 (the “Base Indenture”) among Medtronic Luxco, the Guarantors and Wells Fargo Bank, National Association, as trustee (the “Trustee”), as supplemented by the Fourth Supplemental Indenture dated as of September 29, 2020 (the “Fourth Supplemental Indenture” and together with the Base Indenture, the “Indenture”), among Medtronic Luxco, the Guarantors, the Trustee and Elavon Financial Services DAC, as the paying agent (the “Paying Agent”).
Medtronic Luxco, the Company and Medtronic plc have filed with the Securities and Exchange Commission (the “Commission”) a Registration Statement on Form S-3 (File No. 333-236739) under the Securities Act of 1933, as amended (the “Act”), on February 28, 2020 (the “Registration Statement”) including the prospectus dated as of February 28, 2020 (the “Base Prospectus”), as supplemented by a preliminary prospectus supplement dated as of September 24, 2020 (the “Preliminary Prospectus Supplement”) relating to the Notes, and a prospectus supplement dated as of September 24, 2020 (the “Prospectus Supplement”) relating to the Notes.